Day One Biopharmaceuticals Inc (DAWN) - Total Liabilities
Based on the latest financial reports, Day One Biopharmaceuticals Inc (DAWN) has total liabilities worth $62.91 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore DAWN net asset momentum to track the company's year-over-year net asset growth rate.
Day One Biopharmaceuticals Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Day One Biopharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Day One Biopharmaceuticals Inc (DAWN) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Day One Biopharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Day One Biopharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kuangda Technology Group Co Ltd
SHE:002516
|
China | CN¥798.77 Million |
|
Nokian Renkaat Oyj
HE:TYRES
|
Finland | €1.30 Billion |
|
Bolsa Mexicana de Valores S.A.B. de C.V
MX:BOLSAA
|
Mexico | MX$1.28 Billion |
|
Playtech plc
F:PL8
|
Germany | €823.30 Million |
|
GigaCloud Technology Inc Class A Ordinary Shares
NASDAQ:GCT
|
USA | $716.66 Million |
|
Chengdu Gas Group Co Ltd
SHG:603053
|
China | CN¥2.96 Billion |
|
Sunflower Pharmaceuticals Group Co Ltd
SHE:002737
|
China | CN¥1.25 Billion |
|
China Security & Fire Co Ltd Class A
SHG:600654
|
China | CN¥1.93 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Day One Biopharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Day One Biopharmaceuticals Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Day One Biopharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Day One Biopharmaceuticals Inc (2019–2024)
The table below shows the annual total liabilities of Day One Biopharmaceuticals Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $80.04 Million | +171.24% |
| 2023-12-31 | $29.51 Million | +73.34% |
| 2022-12-31 | $17.02 Million | +96.28% |
| 2021-12-31 | $8.67 Million | +294.23% |
| 2020-12-31 | $2.20 Million | -93.24% |
| 2019-12-31 | $32.52 Million | -- |
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory… Read more